Invention Grant
- Patent Title: Intracellular pH-responsive fusion peptide and pharmaceutical composition for reducing abnormal prion protein aggregation or misfolding
-
Application No.: US15827246Application Date: 2017-11-30
-
Publication No.: US10232012B2Publication Date: 2019-03-19
- Inventor: Yong beom Lim , Chong suk Ryou
- Applicant: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY , INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS
- Applicant Address: KR Seoul KR Gyeonggi-Do
- Assignee: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY,INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS
- Current Assignee: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY,INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS
- Current Assignee Address: KR Seoul KR Gyeonggi-Do
- Agency: Duane Morris LLP
- Agent Gregory M. Lefkowitz; Jason M. Nolan
- Priority: KR10-2016-0161767 20161130
- Main IPC: C07K5/00
- IPC: C07K5/00 ; C07K4/00 ; C07K2/00 ; C07K7/00 ; C07K14/00 ; A61K38/00 ; A61K49/00 ; A61B5/00 ; A61K38/17 ; C07K14/47 ; A61K38/16 ; A61K9/127 ; C07K16/00 ; C07K19/00
Abstract:
A pH-responsive fusion peptide according to the present disclosure, containing a cell-penetrating peptide exhibiting a positive charge, which contains 2-15 arginine residues, and a β-sheet-forming segment, experiences structural change depending on pH change. Due to the structural change, the anti-prion activity and cytotoxicity of the fusion peptide can be controlled as desired.
Public/Granted literature
Information query
